These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 28036283

  • 1. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep 07; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD010383. PubMed ID: 33734432
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Gu X, Zhang Q, Chu YB, Zhao YY, Zhang YJ, Kuo D, Su B, Wu B.
    Lung Cancer; 2019 Jan 18; 127():84-89. PubMed ID: 30642557
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y.
    Ann Oncol; 2017 Oct 01; 28(10):2443-2450. PubMed ID: 28945850
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.
    Mu L, Liu F, Fang Y, He M, Yang M.
    BMJ Open; 2024 Aug 22; 14(8):e081270. PubMed ID: 39179275
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.
    Lung Cancer; 2015 Oct 22; 90(1):71-7. PubMed ID: 26259876
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y, Wang J, Yu Z, Ge H, Zhang LW, Feng LX.
    Clin Transl Sci; 2021 May 22; 14(3):890-897. PubMed ID: 33382908
    [Abstract] [Full Text] [Related]

  • 10. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z.
    Clin Ther; 2013 Jan 10; 35(1):54-65. PubMed ID: 23328269
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y.
    Lancet Oncol; 2013 Sep 10; 14(10):953-61. PubMed ID: 23948351
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K.
    Lung Cancer; 2015 Oct 10; 90(1):65-70. PubMed ID: 26238424
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DB, Ng K.
    BMC Cancer; 2018 Mar 27; 18(1):352. PubMed ID: 29587666
    [Abstract] [Full Text] [Related]

  • 16. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F, Shi Y, Wang Y, Ding L, Yuan X, Sun Y.
    Future Oncol; 2015 Mar 27; 11(3):385-97. PubMed ID: 25675121
    [Abstract] [Full Text] [Related]

  • 17. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X, Han B, Gu A, Zhang Y, Jiao SC, Wang CL, He J, Jia X, Zhang L, Peng J, Wu M, Ying K, Wang J, Ma K, Zhang S, You C, Tan F, Wang Y, Ding L, Sun Y.
    Lung Cancer; 2014 Nov 27; 86(2):207-12. PubMed ID: 25261231
    [Abstract] [Full Text] [Related]

  • 18. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC.
    J Clin Oncol; 2016 Sep 20; 34(27):3258-66. PubMed ID: 27507876
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
    Arrieta O, Anaya P, Morales-Oyarvide V, Ramírez-Tirado LA, Polanco AC.
    Eur J Health Econ; 2016 Sep 20; 17(7):855-63. PubMed ID: 26338546
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
    Li W, Bai R, Qian L, Chen N, Zhao Y, Han F, Bai L, Li J, Yu Y, Cui J.
    Asia Pac J Clin Oncol; 2021 Apr 20; 17(2):e40-e47. PubMed ID: 31957251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.